Sun Yat-Sen Cohort of CNS Idiopathic Inflammatory Demyelinating Diseases
What it found
No result yet.
What it measured
Main measures
Relapse
Through study completion, an average of 5 years
Disability progressionRelapsesMRI lesionsLong-term neurological function
Through study completion, an average of 5 years
Disability progression
Other measures (11)
Long-term neurological function
Baseline, six months, one year, two years, and average three years
Sub-scores of the Expanded Disability Status Scale (EDSS)
Baseline, six months, one year, two years, and average three years
Disability progressionOptical coherence tomography (OCT) of the eyes: retinal nerve fiber layer thickness, macular thickness
Baseline, six months, one year, two years, and average three years
Retina scans (OCT)Changes in humoral immune markers
Baseline, six months, one year, two years, and average three years
Blood or spinal fluid markersChanges in pathogenic antibody titers
Baseline, six months, one year, two years, and average three years
Immune responseP100 amplitude of visual evoked potentials
Baseline, six months, one year, two years, and average three years
Myelin repairP100 latency of visual evoked potentials
Baseline, six months, one year, two years, and average three years
Myelin repairLatency of somatosensory evoked potentials;
Baseline, six months, one year, two years, and average three years
Myelin repairLatency of brainstem auditory evoked potentials;
Baseline, six months, one year, two years, and average three years
Myelin repairAmplitude of somatosensory evoked potentials;
Baseline, six months, one year, two years, and average three years
Myelin repair
Who could take part
Early (CIS/RIS) · 18 to 65
Inclusion Criteria: 1. Patients aged 18-65 years with central nervous system idiopathic inflammatory demyelinating diseases (CNS IIDD); 2. The clinical syndrome of the attack meets one of the following: MS, NMOSD, MOGAD, ADEM, clinically isolated syndrome, demyelinating encephalopathy, demyelinating myelitis, or brainstem encephalitis (see below A-E); 3. Agree to participate in this study and sign the informed consent form. Exclusion Criteria: 1. History of tumors or diagnosis of central nervous system tumors; 2. Infectious lesions of the central nervous system; 3. Hereditary, metabolic, toxic, vascular, or traumatic demyelinating diseases of the brain/spinal cord; 4. Non-compliance with treatment and follow-up.
As registered. Criteria can change, so ask the trial team or your neurologist.
Contact details on the registryAbout this trial
In the sponsor's words
The goal of this observational study is to learn about pathogenesis and clinical prognosis of CNS IIDD in the Chinese population and to provide evidence-based clues for clinical treatment decisions. The main questions it aims to answer are: Question 1: Clarify the clinical characteristics and prognostic factors of various diseases (MS, NMOSD, MOGAD, etc.) within IIDD in the Chinese population. Question 2: Analyze the relationship between biomarkers and the occurrence, progression, and prognosis of CNS IIDD cases in our hospital. Participants will 1. Receive the recommended diagnosis and treatment plans from current international and national guidelines or expert consensus, without additional special interventions. 2. Receive clinical evaluation, follow-up, and management from dedicated neuroimmunology specialists.
Papers
Loading reviews and guidelines…
History
Started
Jan 2024
Main results due
Dec 2035
Finished
Dec 2035
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error